CompletedNot Applicable

Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome

United States24 participantsStarted 2015-08

Plain-language summary

The goal of this study is to determine whether external neuromodulation using repetitive transcranial magnetic stimulation (rTMS) can reduce the perception of self-motion that is experienced by individuals with mal de debarquement syndrome (MdDS). Mal de debarquement is translated as the "sickness of disembarkment," and refers to the chronic feeling of rocking dizziness that occurs after exposure to passive motion. Treatment for MdDS is limited and morbidity is high. The goal of the study is to determine whether rTMS can suppress the rocking dizziness of MdDS.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years old
✓. Willing and capable of interacting with the informed consent process
✓. Primary disorder being a persistent rocking dizziness triggered by passive motion such as from water, land, or air travel and with no other central nervous system or peripheral vestibular disorder determined after appropriate evaluation.

Exclusion criteria

✕. Subjects who cannot comply with study conditions.
✕. Active psychiatric condition such as mania or psychosis
✕. Unstable medical condition
✕. Implanted metal anywhere in the body (infusion pumps, pacemakers, metal or shrapnel in the body, deep brain stimulators, aneurysm clips, metal prostheses, joints, rods or plates). Dental fillings are acceptable.
✕. Personal history of seizures or a first-degree relative with epilepsy
✕. Medications known to lower seizure threshold such as: typical (high-potency) neuroleptics and tricyclic antidepressants: Subjects who take one or a combination of the following drugs will be excluded: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine. clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine (including MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), theophylline, haloperidol, fluphenazine, bupropion.
✕. Pregnancy or planning to become pregnant during study enrollment.

What they're measuring

Dizziness Handicap Inventory

Timeframe: 10 weeks (4 pre stimulation + 6 post stimulation)

Trial details

NCT IDNCT02470377

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-07

Results submitted2022-03-03

View on ClinicalTrials.gov More Mal de Debarquement Syndrome trials